Ascletis Pharma Begins Phase II Study of ASC30 for Diabetes
Ascletis Pharma Inc. has embarked on an exciting new journey in the field of diabetes treatment by dosing the first participants in a groundbreaking 13-week Phase II clinical study with its investigational drug, ASC30. This oral small molecule GLP-1 receptor (GLP-1R) agonist has shown significant promise for the management of type 2 diabetes mellitus.
Significant Weight Loss Results from Previous Studies
Recent trials have demonstrated that ASC30 is capable of inducing placebo-adjusted weight loss of up to 7.7%. In one of the prior 13-week Phase II studies focusing on participants living with obesity or overweight conditions, ASC30 proved effective while exhibiting an excellent gastrointestinal tolerability profile. Remarkably, there were no observed safety signals regarding liver health. The results from this earlier study add to the anticipation surrounding the ongoing diabetes study.
Details of the Phase II Study for Diabetes
The current Phase II trial of ASC30 aims to delineate the drug’s efficacy, safety, and tolerability specifically in participants suffering from type 2 diabetes. Randomized and double-blind, this multi-center study will enroll around 100 individuals, categorizing them into groups based on their assigned dosages: 40 mg, 60 mg, and 80 mg. The primary endpoint centers on evaluating the mean change in HbA1c levels from the baseline at the end of the 13-week treatment period, in comparison with the placebo group. Alongside this, secondary measures will evaluate fasting blood glucose levels and overall body weight changes during the trial.
Expanding Market Opportunities
As Ascletis continues to innovate, CEO Jinzi Jason Wu emphasized the strategic importance of broadening the clinical focus of ASC30 into the diabetes treatment market. This next step is crucial as it aligns with the company’s mission to provide effective treatment options for patients managing diabetes. By offering a once-daily oral treatment option, Ascletis aims to enhance the living standards and health outcomes for those affected by this chronic condition.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. stands as a forward-thinking, fully integrated biotechnology company dedicated to addressing metabolic diseases through innovative therapies. By harnessing advanced technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery and a proprietary Ultra-Long-Acting Platform, Ascletis is well-poised to introduce best-in-class treatments to the market. Their lead program, ASC30, effectively encapsulates the company’s ethos and commitment to improving patient outcomes in weight management and diabetes through scientifically backed treatments.
Frequently Asked Questions
What is ASC30 and what is its primary use?
ASC30 is a GLP-1R agonist being investigated for its effectiveness in treating type 2 diabetes and obesity.
When are results from the Phase II study expected?
Topline data from the Phase II study are anticipated to be available in the third quarter of 2026.
What parameters are being measured in the Phase II study?
The primary measurement is the change in HbA1c levels, alongside secondary measures like fasting blood glucose and body weight changes.
How does ASC30 compare to other treatments?
ASC30 aims to provide a once-daily oral option, potentially improving adherence and effectiveness compared to other treatments.
What is the goal of Ascletis in this clinical study?
Ascletis aims to validate the efficacy and safety of ASC30, establishing it as a leading treatment option for diabetes.
